PI-RR: A Reporting System for Local Prostate Cancer Recurrence Evaluation After Radiation Therapy or Radical Prostatectomy Authors: June Young Seo Published: 2025 ABSTRACT AbstractBiochemical recurrence, marked by rising prostate specific antigen levels, is a common and challenging clinical scenario following curative treatments for localized prostate cancer (PCa), such as radical prostatectomy (RP) or radiation therapy (RT). An accurate assessment is critical for detecting local recurrence and distinguishing it from distant metastatic disease, thereby guiding salvage therapies. While multiparametric MRI has demonstrated strong performance in detecting local recurrence, the lack of standardized reporting has historically limited its clinical utility and reproducibility. To address this variability, an international consensus-based Prostate Imaging for Recurrence Reporting (PI-RR) system was introduced in 2021. PI-RR adopts a 5-point Likert scale, similar to Prostate Imaging Reporting and Data System, but places greater emphasis on dynamic contrast-enhanced MRI and incorporates knowledge of the prior primary tumor location to grade the likelihood of recurrence. This review article provides a comprehensive overview of the PI-RR system, detailing its imaging acquisition recommendations, specific scoring criteria after RT and RP, clinical implications, and future directions within the evolving landscape of PCa imaging.Keywords: Prostate Cancer, Biochemical Recurrence, Multiparametric MRI, PI-RR, Dynamic Contrast-Enhanced MRI, Diffusion-Weighted Imaging INTRODUCTION Prostate cancer (PCa) is a significant global health concern (1). Radical prostatectomy (RP) and radiation therapy (RT) are established treatments with curative intent for patients with localized disease (2). However, 27%–53% of treated patients experience biochemical recurrence (BCR) (3). This presents a diagnostic dilemma: BCR due to treatable local recurrence or the manifestation of distant systemic disease (4). Management of these patients critically depends on accurate disease localization (5). In this post-treatment setting, multiparametric MRI (mpMRI) has emerged as an indispensable tool for noninvasive assessment of the treated prostate bed or remnant gland (6). Recurrent PCa typically presents as a focus of cellularity (restricted diffusion) and enhanced neoangiogenesis (early contrast enhancement) (7,8). Despite the proven accuracy of mpMRI, the transition from the Prostate Imaging Reporting and Data System (PI-RADS) v2.1 framework, designed for the native gland (9), to the post-treatment environment is challenging (10). Treatment-related changes, such as diffuse fibrosis and volume reduction after RT (11) or scar tissue and architectural distortion after RP, substantially alter the expected T2-weighted imaging (T2WI) signal intensity (7,12). This fundamental alteration renders the conventional interpretation highly subjective and variable among readers (13). Recognizing the need for standardization in this complex scenario, an international expert panel published the Prostate Imaging for Recurrence Reporting (PI-RR) guidelines in 2021 (4,14). The PI-RR provides a structured, universally applicable framework to standardize the performance, interpretation, and reporting of mpMRI for local recurrence, thereby facilitating communication among radiologists, urologists, and radiation oncologists (4). The PI-RR system explicitly shifts the diagnostic focus by prioritizing functional sequences over T2WI to address post-treatment anatomical changes (10). MRI ACQUISITION GUIDELINES The PI-RR system recommends following the technical standards of PI-RADS v2.1 for mpMRI sequences, such as T2WI, diffusion-weighted imaging (DWI), and dynamic contrast-enhanced (DCE)-MRI (4,5,9). However, specific adjustments are crucial for optimizing imaging of post-treatment anatomy and minimizing artifacts (10). • T2WI: For post-RP patients, PI-RR specifically recommends obtaining three orthogonal planes (axial, coronal, and sagittal) of T2WI (5,10,15). This is essential for the detailed evaluation of the vesicourethral anastomosis (VUA) and adjacent structures, which are common sites of recurrence (5,10,15). • Field of view (FOV): In addition to small FOV mpMRI sequences, at least one large FOV sequence (T1WI or DWI) is required to screen for suspicious lymphadenopathy or bone metastases, which signify systemic progression (5,10,15). • DCE-MRI DCE plays a critical role because focal early enhancement is a hallmark of recurrence (7,10). The use of subtracted DCE images is highly recommended to enhance the visualization of subtle early enhancements, particularly in scar tissue or radiation-altered glands (10,16). • Timing of MRI: To avoid confounding inflammatory changes, mpMRI should be performed at least 3 months after RP and at least 3 months after RT (4,5,7). • Artifact management: Post-surgical clips or brachytherapy seeds can cause susceptibility artifacts, often severely degrading DWI and DCE images (7,10,17). Metal artifact reduction techniques may be helpful in these cases (10). PI-RR SCORING SYSTEM: A SHIFT IN DIAGNOSTIC PARADIGM The PI-RR system employs a 5-point Likert scale, ranging from PI-RR 1 (very low likelihood of recurrence) to PI-RR 5 (very high likelihood), to assess the overall suspicion of local recurrence (4,5). A defining feature of PI-RR is the explicit consideration of the primary tumor location, which increases the suspicion score if the new finding corresponds to the site of the original disease (5,10). T2WI provides essential anatomical information but does not determine the final PI-RR assessment score after either RT or RP (5,10). POST-RT ASSESSMENT Following RT, the prostate gland typically exhibits glandular loss and fibrosis as the predominant histopathological changes, resulting in a diffusely low signal intensity on T2-weighted images. Therefore, T2WI has limited utility in differentiating recurrence from post-treatment changes (10,12). However, recurrent tumors typically exhibit diffusion restriction due to high cellularity and early hyperenhancement secondary to neovascularization, similar to the imaging features of the original tumor. Therefore, both DWI and DCE are co-dominant after RT (5,10). Recurrences are typically confined to the site of the original primary tumor; therefore, lesions that are clearly visualized on DWI or DCE images and correspond to the location of the original tumor are assigned higher scores (5,15). The criteria for score assignment after RT in each MRI sequence are summarized in Table 1, and the process for determining the final PI-RR category based on these individual scores is illustrated in Fig. 1. Table 1Assessment Categories by MRI Sequence After Radiation TherapySequenceScore Decision DominancyScorePattern ChangesDWIDominant1No abnormality on high b-value DWI and ADC map2Diffuse moderate hyperintensity on high b-value DWI and/or diffuse moderate hypointensity on the ADC map3Focal marked hyperintensity on high b-value DWI or focal marked hypointensity on the ADC map, but not on both4Focal marked hyperintensity on high b-value DWI and marked hypointensity on the ADC map not at the same site as the primary tumour, or site of the primary tumour not known5Focal marked hyperintensity on high b-value DWI and marked hypointensity on the ADC map at the same site as the primary tumourDCEDominant1No enhancement2Diffuse or heterogeneous enhancement3Focal or mass-like late enhancement4Focal or mass-like early enhancement not at the same site as the primary tumour, or tumour site not known5Focal or mass-like early enhancement at the same site as the primary tumourT2WINon-dominant1No abnormal signal intensity compared to the background2Linear, wedge-shaped, or diffuse moderate hypointensity or residual BPH nodules3Focal or mass like mild hypointensity not at the primary tumour site; includes others than do not qualify as 2, 4, or 54Focal or mass-like moderate hypointensity not at the same site as the primary tumour, or location of primary tumour not known5Focal or mass-like marked hypointensity at the same site as the primary tumourADC = apparent diffusion coefficient, BPH = benign prostatic hyperplasia, DCE = dynamic contrast enhancement, DWI = diffusion-weighted imaging, T2WI = T2-weighted imaging Assessment Categories by MRI Sequence After Radiation Therapy ADC = apparent diffusion coefficient, BPH = benign prostatic hyperplasia, DCE = dynamic contrast enhancement, DWI = diffusion-weighted imaging, T2WI = T2-weighted imaging Final PI-RR assessment score for local recurrence after radiation therapy. The final PI-RR category is determined by the sequence with higher score between DCE score and DWI score. If both DCE and DWI scores are 4, the final category is upgraded to 5. DCE = dynamic contrast enhancement, DWI = diffusion-weighted imaging, PI-RR = Prostate Imaging for Recurrence Reporting • Overall PI-RR score: The score was determined by the higher scores of the DWI and DCE sequences (4,5). • Upgrading rule: If both DWI and DCE score 4 points and the findings (marked restricted diffusion and focal early enhancement) co-localize, the overall score is upgraded to PI-RR 5 (4,5). Examples corresponding to PI-RR scores 4 and 5 after RT are presented in Fig. 3 and Fig. 4. PI-RR 5 local recurrence in a 68-year-old man who underwent radiation therapy for prostate cancer. A, B. At the time of initial diagnosis, axial T2-weighted image (A) and high b-value DWI (b = 1,400) (B) demonstrate a PI-RADS 5 large extent prostate cancer involving almost the entire prostate gland (arrows), predominantly on the left side. The lesion was confirmed as Gleason score 4 + 4 prostate cancer on biopsy, and the initial serum PSA level was 25.1 ng/mL. After radiation therapy, serum PSA level remained at an undetectable nadir (<0.006 ng/mL); however, 2 years after treatment, the PSA level rose to 0.312 ng/mL, prompting MRI evaluation. C-E. Axial T2-weighted image (C) shows no definite lesion. High b-value DWI (b = 1,500) (D) reveals a lesion with marked hyperintensity in the apical left anterior transitional zone (arrowheads), which corresponds to an area of marked hypointensity on the apparent diffusion coefficient map (E) (arrowheads). F. On the DCE image, the lesion demonstrates mild early enhancement (arrowheads). This recurrent mass developed at the same site as the primary tumor. After radiation therapy, the lesion was assigned a DWI and DCE scores of 5, resulting in an overall PI-RR score of 5. Biopsy confirmed recurrent prostate cancer, and the patient showed a subsequent decrease in serum PSA level after salvage radiation therapy. DCE = dynamic contrast-enhancement, DWI = diffusion-weighted imaging, PI-RADS = Prostate Imaging Reporting and Data System, PI-RR = Prostate Imaging for Recurrence Reporting, PSA = prostate specific antigen PI-RR 4 & 5 local recurrence in a 77-year-old man who underwent radiation therapy for prostate cancer. A, B. At the time of initial diagnosis, axial T2-weighted image (A) and high b-value DWI (b = 1,500) (B) demonstrate a PI-RADS 5 large extent prostate cancer involving the bilateral mid to basal transitional zones (arrows), predominantly on the left side. The lesion was confirmed as Gleason score 4 + 4 prostate cancer on biopsy. After radiation therapy, the serum PSA level remained undetectable at a nadir (<0.006 ng/mL); however, 2 years and 5 months post-treatment, the PSA level rose to 0.473 ng/mL, prompting an MRI evaluation. C-E. Axial T2-weighted image (C) shows no definite lesion. High b-value DWI (b = 1,500) (D) reveals marked hyperintensity in the mid right posterolateral peripheral zone (arrowhead), and apparent diffusion coefficient image (E) shows a dot-like lesion with marked hypointensity (arrowhead). F. On the DCE image, this lesion demonstrates early strong enhancement (arrowhead). Additionally, a smaller lesion, showing early strong enhancement, is located just anterior to the main lesion (point line arrow). This recurrent mass is located at a different site from the primary tumor. After radiation therapy, the posterior lesion (arrowhead) was assigned DWI and DCE scores of 4, resulting in an overall PI-RR score of 5. The anterior lesion (point line arrow) was assigned a DCE score of 4 and a DWI score of 1 or 2, resulting in an overall PI-RR score of 4. Biopsy confirmed recurrent prostate cancer, and the patient underwent additional radiation therapy, after which serum PSA level decreased. DCE = dynamic contrast enhancement, DWI = diffusion-weighted imaging, PI-RADS = Prostate Imaging Reporting and Data System, PI-RR = Prostate Imaging for Recurrence Reporting, PSA = prostate specific antigen POST-RP ASSESSMENT After RP, recurrence occurs predominantly in the VUA and surrounding soft tissue (5,15). Scarring and fibrosis severely limit the utility of T2WI and DWI (7,12). Consequently, DCE is the dominant sequence for PI-RR scoring after RP (4,5). The criteria for score assignment after RP in each MRI sequence are summarized in Table 2, and the process for determining the final PI-RR category based on these individual scores is illustrated in Fig. 2. Table 2Assessment Categories by MRI Sequence After Radical ProstatectomySequenceScore Decision DominancyScorePattern ChangesDCEDominant1No enhancement2Diffuse or heterogeneous enhancement3Focal or mass-like late enhancement4Focal or mass-like early enhancement not on the same side as the primary tumour, or tumour side not known5Focal or mass-like early enhancement on the same side as the primary tumourDWISupplementary1No signal abnormality on high b-value DWI and ADC map2Diffuse moderate hyperintensity on high b-value DWI and diffuse moderate hypointensity on the ADC map3Focal marked hyperintensity on high b-value DWI or focal marked hypointensity on the ADC map, but not on both4Focal marked hyperintensity on high b-value DWI and marked hypointensity on the ADC map not on the same side as the primary tumour, or side of the primary tumour not known5Focal marked hyperintensity on high b-value DWI and marked hypointensity on the ADC map on the same side as the primary tumourT2WINon-dominant1Normal hypointense vesicourethral anastomosis and seminal vesicle bed remnants2Diffuse thickening of the vesicourethral anastomosis and/or thick-walled seminal vesicle remnants and/or coarse scar tissue within the seminal vesicle beds3Symmetric focal or mass-like signal intensity in the perianastomotic area or seminal vesicle bed(s)4Asymmetric focal or mass-like iso/hyperintensity in the perianastomotic area or seminal vesicle bed(s) not on the same side as the primary tumour, or tumour side not known5Asymmetric focal or mass-like iso/hyperintensity in the perianastomotic area or seminal vesicle bed(s) on the same side as the primary tumourADC = apparent diffusion coefficient, DCE = dynamic contrast enhancement, DWI = diffusion-weighted imaging, T2WI = T2-weighted imaging Assessment Categories by MRI Sequence After Radical Prostatectomy ADC = apparent diffusion coefficient, DCE = dynamic contrast enhancement, DWI = diffusion-weighted imaging, T2WI = T2-weighted imaging Final PI-RR assessment score for local recurrence after radical prostatectomy. The final PI-RR category is determined by the DCE score. DCE score 2 or 3 is upgraded to the final PI-RR category 3 or 4, if DWI score is 4 or 5. DCE = dynamic contrast enhancement, DWI = diffusion-weighted imaging, PI-RR = Prostate Imaging for Recurrence Reporting • Overall PI-RR score: Scores 1, 4, and 5 are derived directly from the DCE score (4). • Upgrading rule: If the DCE score is 2 or 3 and the DWI score is 4 or 5, the overall PI-RR score is upgraded by one point (4). Therefore, DWI plays an adjunctive role (10). Examples corresponding to PI-RR scores 4 and 5 after RP are presented in Fig. 5 and Fig. 6. PI-RR 5 local recurrence at the operation bed in a 65-year-old man who underwent radical prostatectomy for prostate cancer. A-E. Preoperative axial T2-weighted image (A) and high b-value DWI (b = 1,500) (B) demonstrate a large extent of prostate cancer involving the bilateral peripheral zones (arrows), predominantly on the right side. The patient's preoperative serum PSA level was 24.5 ng/mL, and the prostatectomy specimen revealed Gleason score 5 + 5 prostate cancer. After radical prostatectomy, the patient's serum PSA level remained at an undetectable nadir (<0.006 ng/mL); however, at approximately 16 months postoperatively, the PSA level rose to 0.293 ng/mL, prompting MRI evaluation. Axial T2-weighted image (C) shows an elongated T2 intermediate signal intensity lesion at the 8–9 o'clock position of the vesicourethral anastomosis (arrowheads). The lesion exhibits marked hyperintensity on high b-value DWI (D) (arrowheads) and marked hypointensity on the apparent diffusion coefficient map (E) (arrowheads). F. DCE image demonstrates early enhancement of the lesion (arrowheads). This recurrent mass developed at the same site as the primary tumor. After radical prostatectomy, the lesion was assigned DCE and DWI scores of 5, resulting in an overall PI-RR score of 5. Biopsy confirmed recurrent prostate cancer, and the patient subsequently underwent salvage radiation therapy, after which serum PSA level returned to an undetectable nadir. DCE = dynamic contrast enhancement, DWI = diffusion-weighted imaging, PI-RR = Prostate Imaging for Recurrence Reporting, PSA = prostate specific antigen PI-RR 4 local recurrence at the operation bed in a 70-year-old man who underwent radical prostatectomy for prostate cancer. A, B. Preoperative axial T2-weighted image (A) and high b-value DWI (b = 1,400) (B) demonstrate a PI-RADS 5 large extent prostate cancer predominantly involving the bilateral peripheral zones and transitional zone at the base (arrows), with more extensive disease on the right side. The patient's preoperative serum PSA level was 16.2 ng/mL, and the prostatectomy specimen revealed Gleason score 4 + 5 prostate cancer. After radical prostatectomy, serum PSA level remained at an undetectable nadir (<0.006 ng/mL); however, at approximately 10 months postoperatively, the PSA level rose to 0.58 ng/mL, prompting MRI evaluation. C-E. On axial T2-weighted image (C), no definite lesion is identified around the vesicourethral anastomosis. Although there is no marked hyperintensity on high b-value DWI (D), an area of mild hypointensity is observed on the apparent diffusion coefficient map (E) at the 4–5 o'clock position of the vesicourethral anastomosis (point line arrow). F. On the DCE image, this lesion shows early and strong enhancement (point line arrow). This recurrent mass developed at the contralateral vesicourethral anastomosis site relative to the primary tumor. After radical prostatectomy, the lesion was assigned a DCE score of 4 and a DWI score of 3, resulting in an overall PI-RR score of 4. Biopsy confirmed recurrent prostate cancer, and the patient subsequently underwent salvage radiation therapy, after which serum PSA level returned to an undetectable nadir. DCE = dynamic contrast enhancement, DWI = diffusion-weighted imaging, PI-RADS = Prostate Imaging Reporting and Data System, PI-RR = Prostate Imaging for Recurrence Reporting, PSA = prostate specific antigen CLINICAL IMPLICATIONS AND THE ROLE OF PI-RR The PI-RR score offers robust, standardized risk stratification that informs subsequent clinical decisions, although it should be integrated with conventional risk factors (4). • PI-RR 1-2 (Very Low to Low Likelihood): The focus shifts to ruling out distant disease using highly sensitive modalities, such as prostate-specific membrane antigen (PSMA) PET/CT (4). Salvage RT may still be considered after RP based on the clinical guidelines, irrespective of the imaging results (4). • PI-RR 3 (Equivocal/Indeterminate): Targeted biopsy is generally indicated to obtain histopathological confirmation, especially for post-RT patients, where definitive salvage therapy carries a risk of morbidity (4,5). For post-RP patients, further imaging or biopsy is recommended, particularly if the PSA levels exceed 1 ng/mL (4). • PI-RR 4-5 (High to Very High Likelihood): Strong recommendation for a biopsy (for post-RT) or moving towards salvage treatment (for post-RP) (4). Staging with highly sensitive nuclear medicine scans (e.g., PSMA PET/CT) should precede definitive local treatment to confirm the absence of systemic disease (4). PI-RR AND PSMA PET/CT INTEGRATION The emergence of PSMA PET/CT has profoundly affected the evaluation of BCR (5,18). PSMA PET offers exceptional sensitivity for low PSA levels but can be limited in the local setting, particularly near the VUA after RP, due to urinary tracer excretion (4,5). Therefore, the PI-RR system plays a crucial, complementary role (4). • Targeting biopsy: PI-RR is essential for guiding MRI-US fusion biopsies (5). • Addressing PSMA indeterminacy: In cases where PSMA-PET is negative or equivocal, PI-RR provides the necessary local anatomical and functional assessments (4,10). The synergy between the local details provided by PI-RR and the high molecular sensitivity of PSMA-PET is increasingly recognized as the optimal diagnostic approach for BCR (10). CONCLUSION AND FUTURE PERSPECTIVES The introduction of the PI-RR system represents a paradigm shift toward standardized evidence-based reporting of local PCa recurrence (4,19). By carefully adapting PI-RADS principles to post-treatment anatomy and prioritizing functional sequences, PI-RR enhances the reliability of mpMRI (4,10). Early studies have demonstrated the system's excellent inter-reader reproducibility and promising diagnostic performance, bolstering its utility in clinical practice (5,20). Looking ahead, several key areas require focus: • Prospective validation: PI-RR requires extensive prospective multi-institutional studies to validate its clinical efficacy across diverse patient populations and levels of reader experience (4). • Integration with focal therapy: Currently, the PI-RR does not provide specific guidelines for evaluating recurrence after focal therapy (4,5). Developing a PI-RR adapted for this setting is a critical next step (5). • Formal PSMA integration: To maximize the diagnostic yield, the next version of the PI-RR is likely to incorporate PSMA PET findings, leading to a comprehensive multimodal reporting system (10). In summary, PI-RR is poised to significantly improve patient care by facilitating the precise detection and localization of local recurrence, thereby enabling clinicians to transition from a single-modality approach to an integrated, personalized diagnostic strategy for patients with BCR (4). Footnotes Conflicts of Interest: The author has no potential conflicts of interest to disclose. Funding: None Supplementary Materials Korean translation of this article is available with the Online-only Data Supplement at https://doi.org/10.3348/jksr.2025.0108. SUPPLEMENTARY MATERIAL References Associated Data Supplementary Materials SUPPLEMENTARY MATERIAL